RAPP
$27.73
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Recent News
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. Indeed, Rapport Therapeutics...
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff?
Rapport Therapeutics announced in early January 2026 that the FDA has cleared RAP-219 to move into Phase 3 registrational trials for focal onset seizures, while the company advances a broader neuroscience pipeline spanning epilepsy, bipolar mania, chronic pain and migraine. A key nuance is that, even as the FDA lifted a clinical hold on Rapport’s diabetic peripheral neuropathic pain program, the company is directing resources toward its α6β4 pain franchise and epilepsy portfolio,...